124 related articles for article (PubMed ID: 17908981)
1. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response.
Ferry DR; Anderson M; Beddard K; Tomlinson S; Atherfold P; Obszynska J; Harrison R; Jankowski J
Clin Cancer Res; 2007 Oct; 13(19):5869-75. PubMed ID: 17908981
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
Janmaat ML; Gallegos-Ruiz MI; Rodriguez JA; Meijer GA; Vervenne WL; Richel DJ; Van Groeningen C; Giaccone G
J Clin Oncol; 2006 Apr; 24(10):1612-9. PubMed ID: 16575012
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response.
Javle M; Pande A; Iyer R; Yang G; LeVea C; Wilding G; Black J; Nava H; Nwogu C
Am J Clin Oncol; 2008 Aug; 31(4):329-34. PubMed ID: 18845990
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
Goncalves A; Fabbro M; Lhommé C; Gladieff L; Extra JM; Floquet A; Chaigneau L; Carrasco AT; Viens P
Gynecol Oncol; 2008 Jan; 108(1):42-6. PubMed ID: 17980406
[TBL] [Abstract][Full Text] [Related]
5. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
Kim DW; Lee SH; Lee JS; Lee MA; Kang JH; Kim SY; Shin SW; Kim HK; Heo DS
Lung Cancer; 2011 Jan; 71(1):65-9. PubMed ID: 20430469
[TBL] [Abstract][Full Text] [Related]
6. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.
Oh IJ; Ban HJ; Kim KS; Kim YC
Lung Cancer; 2012 Jul; 77(1):121-7. PubMed ID: 22333554
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
Rothenberg ML; LaFleur B; Levy DE; Washington MK; Morgan-Meadows SL; Ramanathan RK; Berlin JD; Benson AB; Coffey RJ
J Clin Oncol; 2005 Dec; 23(36):9265-74. PubMed ID: 16361624
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
Rojo F; Tabernero J; Albanell J; Van Cutsem E; Ohtsu A; Doi T; Koizumi W; Shirao K; Takiuchi H; Ramon y Cajal S; Baselga J
J Clin Oncol; 2006 Sep; 24(26):4309-16. PubMed ID: 16963731
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Argiris A; Mittal N
Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.
Lara-Guerra H; Waddell TK; Salvarrey MA; Joshua AM; Chung CT; Paul N; Boerner S; Sakurada A; Ludkovski O; Ma C; Squire J; Liu G; Shepherd FA; Tsao MS; Leighl NB
J Clin Oncol; 2009 Dec; 27(36):6229-36. PubMed ID: 19884551
[TBL] [Abstract][Full Text] [Related]
13. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
14. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Canil CM; Moore MJ; Winquist E; Baetz T; Pollak M; Chi KN; Berry S; Ernst DS; Douglas L; Brundage M; Fisher B; McKenna A; Seymour L
J Clin Oncol; 2005 Jan; 23(3):455-60. PubMed ID: 15659491
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
Liam CK; Pang YK; Leow CH
Respirology; 2006 May; 11(3):287-91. PubMed ID: 16635086
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402.
Kobayashi M; Matsui K; Katakami N; Takeda K; Moriyama A; Iwamoto Y; Takada M; Yoshioka H; Sueoka-Aragane N; Nakagawa K;
Jpn J Clin Oncol; 2011 Aug; 41(8):948-52. PubMed ID: 21715363
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
Small EJ; Fontana J; Tannir N; DiPaola RS; Wilding G; Rubin M; Iacona RB; Kabbinavar FF
BJU Int; 2007 Oct; 100(4):765-9. PubMed ID: 17822457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
